Company: VERA
Filing Date: 2025-05-19
Form Type: 8-K
Source: 0000950170-25-074446
Chunk: 1

Company: Vera Therapeutics, Inc.
Filing Date: 2025-05-19
Form: 8-K
Item: Item 5.07
Chunk 1
---
───────────────────────────────────────
  52,984,920      1,876,215        5,128             1,795,714  

Proposal 4 - Advisory Vote on the Frequency of Stockholder Votes on Executive Compensation.

The Company’s stockholders indicated, on an advisory basis, the preferred frequency of every year for future stockholder advisory votes regarding compensation awarded to the Company’s named executive officers, as disclosed in the Proxy Statement. In light of the vote of the stockholders on this proposal and consistent with the recommendation of the Company’s Board of Directors, the Company will include a non-binding stockholder advisory vote to approve the compensation of its named executive officers in its proxy materials every year. The Company will hold such annual advisory votes until the next required vote on the frequency of stockholder votes on named executive officer compensation. The Company is required to hold votes on the frequency of holding future non-binding advisory votes on executive compensation every six calendar years. The final voting results are as follows:

    One Year      Two Years      Three Years      Abstain      Broker Non-Votes  
 ─────────────────────────────────────────────────────────────────────────────────
  54,795,647          1,080           65,201        4,335             1,795,714  

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

                                        Vera Therapeutics, Inc.      
  Date:      May 19, 2025      By:      /s/ Marshall Fordyce, M. D.  
                                        Marshall Fordyce, M. D.      

  Chief Executive Officer